GHP Investment Advisors Inc. Has $7.78 Million Position in Johnson & Johnson (NYSE:JNJ)

GHP Investment Advisors Inc. boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 5.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,813 shares of the company’s stock after purchasing an additional 2,367 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $7,777,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co lifted its position in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its position in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after buying an additional 82,429 shares during the last quarter. IFM Investors Pty Ltd lifted its position in shares of Johnson & Johnson by 20.1% during the 1st quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock worth $74,259,000 after buying an additional 70,221 shares during the last quarter. Essex LLC lifted its position in shares of Johnson & Johnson by 3.7% during the 1st quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after buying an additional 1,146 shares during the last quarter. Finally, Hardy Reed LLC lifted its position in shares of Johnson & Johnson by 2.7% during the 1st quarter. Hardy Reed LLC now owns 5,098 shares of the company’s stock worth $904,000 after buying an additional 133 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Raymond James lowered their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Atlantic Securities lowered their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Finally, Sanford C. Bernstein lowered their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ stock opened at $176.82 on Wednesday. The stock has a market cap of $462.29 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 3.49 and a beta of 0.57. The stock has a 50-day moving average of $168.35 and a 200-day moving average of $171.28. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the prior year, the company earned $2.60 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson declared that its Board of Directors has initiated a stock repurchase program on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Activity at Johnson & Johnson

In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the transaction, the insider now owns 80,236 shares in the company, valued at $13,764,485.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders have sold a total of 135,723 shares of company stock worth $23,192,574 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.